The NYT had a front page article on the decision by regulators in the United States and Europe to restrict access to Avandia, a major drug for treating diabetes. The reason for the restriction was a new study that linked the drug to tens of thousands of heart attacks.
This assessment was based on an independent analysis of data from GlaxoSmithKline, the manufacturer of the drug. GlaxoSmithKline did not do (or report) this analysis itself even though it had the data. The patent monopoly on Avandia granted by the government gave GlaxoSmithKline a strong incentive not to find the potential dangers of its drug. This failure of big government should have been noted in this article. (There are more efficient alternatives to patent monopolies for supporting prescription drug research.)